Breaking News, Collaborations & Alliances

AavantiBio, Catalent Enter Gene Therapy Alliance

Aims to advance AavantiBio’s gene therapy pipeline, including its lead program in Friedreich’s Ataxia (FA)

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AavantiBio, a gene therapy company focused on rare genetic diseases, and Catalent entered a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).   Catalent will provide process development and CGMP manufacturing of AavantiBio’s adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the U.S. and Europe. Catalent will further support process optimization and look to ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters